Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute myeloid leukaemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    406 result(s) found for: Acute myeloid leukaemia. Displaying page 3 of 21.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-019377-15 Sponsor Protocol Number: TUD-ETAL-1-045 Start Date*: 2010-11-04
    Sponsor Name:Technische Universität Dresden
    Full Title: Randomisierte Studie zur allogenen hämatopoetischen Stammzelltransplantation im Vergleich zur Standardchemotherapie bei Patienten in erster kompletter Remission im Alter von <=60 Jahren mit AML int...
    Medical condition: Hematopoietic stem cell transplantation in patients with newly diagnoses AML ≤60 years of age in intermediate risk, after first complete response in comparison to standard consolidation chemotherap...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004710-41 Sponsor Protocol Number: AMLBFM0401 Start Date*: 2006-11-26
    Sponsor Name:St. Anna Kinderkrebsforschung
    Full Title: Multizentrische Therapieoptimierungsstudie AML-BFM 2004 zur Behandlung der akuten myeloischen Leukämien bei Kindern und Jugendlichen Multicentric therapy optimizing study AML-BFM 2004 for the trea...
    Medical condition: For acute myeloic leukaemia in children and juveniles improvment of treatment with new medications should be investigated: 1. Cladribine: originally licenced for hairy cell leukamia has shown good ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001941 AML LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005872-42 Sponsor Protocol Number: 0103-007 Start Date*: 2007-01-31
    Sponsor Name:Pharmion GmbH
    Full Title: A Phase II study of MGCD0103 (MG-0103) in patients with acute myelogenous leukemia/high risk MDS who are elderly and have previously untreated disease or who are adult and have relapsed/refractory ...
    Medical condition: Acute myelogenous leukemia or high risk myelodysplastic syndromes in patients who are elderly and have previously untreated disease or who are adult and have relapsed or refractory disease.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005562-39 Sponsor Protocol Number: P060205 Start Date*: 2008-08-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: ALFA 0703 : A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Chemotherapy or azacitidine as salvage therapy and Azacitidine as Mai...
    Medical condition: Older patients with acute myeloblastic leukemia (AML).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000878 LAM PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002983-32 Sponsor Protocol Number: CLBH589B2213 Start Date*: 2009-06-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML)
    Medical condition: Patients with refractory de novo or secondary acute myelogenous leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018418-53 Sponsor Protocol Number: CSTI571A2110 Start Date*: 2010-06-01
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia...
    Medical condition: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009015 Chronic myeloid leukemia LLT
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) NL (Prematurely Ended) HU (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001082-15 Sponsor Protocol Number: IPC2006-07 Start Date*: 2008-07-31
    Sponsor Name:Institut Paoli Calmette
    Full Title: Etude de Phase I-II multicentrique de l'association Cloretazine-Daunorubicine-Aracytine dans le traitement des leucémies aigües myéloïdes du groupe cytogénétique défavorable.
    Medical condition: Malades atteints de Leucémie Aigüe Myéloïde
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024346 Leukemia myeloblastic acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020432-18 Sponsor Protocol Number: LAMAN-01AN Start Date*: 2011-05-03
    Sponsor Name:ASOCIACION ANDALUZA DE HEMATOLOGIA Y HEMOTERAPIA
    Full Title: TRATAMIENTO DE MANTENIMIENTO CON 5-AZACITIDINA EN PACIENTES CON LEUCEMIA MIELOBLÁSTICA AGUDA NO ELEGIBLES PARA TRATAMIENTO INTENSIVO Y CON RESPUESTA PARCIAL O COMPLETA TRAS QUIMIOTERAPIA DE INDUCCIÓN
    Medical condition: PACIENTES CON LEUCEMIA MIELOBLÁSTICA AGUDA NO ELEGIBLES PARA TRATAMIENTO INTENSIVO Y CON RESPUESTA PARCIAL O COMPLETA TRAS QUIMIOTERAPIA DE INDUCCIÓN
    Disease: Version SOC Term Classification Code Term Level
    13 10024346 Leucemia mieloblástica aguda LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001430-14 Sponsor Protocol Number: peg-filgrastim Vs filgrastim nel t Start Date*: 2007-02-19
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: Peg-filgrastim Vs filgrastrim in pediatric patients.
    Medical condition: haematologic malignant tumors
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000880 PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004968-40 Sponsor Protocol Number: TUD-SORAML-034 Start Date*: 2009-02-20
    Sponsor Name:Technische Universität Dresden
    Full Title: A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age
    Medical condition: Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10001941 AML LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003581-34 Sponsor Protocol Number: DASATINIB compassionate use Start Date*: 2006-07-27
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: DASATINIB compassionate use
    Medical condition: CML and Ph
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000880 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004050-16 Sponsor Protocol Number: HEAT-AML Start Date*: 2019-08-01
    Sponsor Name:University Hospital Karolinska
    Full Title: HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multicenter study to assess the tolerability and efficacy of the addition of hydroxyurea to standard a...
    Medical condition: Newly diagnosed acute myeloid leukaemia (AML) in patients ≥ 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024291 Leukaemias acute myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003482-28 Sponsor Protocol Number: SGN33A-005 Start Date*: 2016-07-14
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed ac...
    Medical condition: Acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) BE (Completed) AT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000981-40 Sponsor Protocol Number: SWEAML12-A Start Date*: 2013-01-23
    Sponsor Name:The Swedish AML Group
    Full Title: Azacitidine compared to conventional chemotherapy in consolidation of elderly patients (> 65 years) with AML in first complete remission
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10024348 Leukemia myelogenous LLT
    14.1 100000004864 10000835 Acute leukemia LLT
    14.1 100000004864 10024307 Leukaemia myelogenous LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002487-27 Sponsor Protocol Number: 1230.14 Start Date*: 2013-01-21
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients ≥...
    Medical condition: previously untreated acute myeloid leukaemia in patients ≥ 65 years and ineligible for intensive remission induction therapy
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) GR (Completed) AT (Completed) FI (Completed) ES (Completed) IT (Completed) CZ (Completed) NL (Completed) HU (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005207-32 Sponsor Protocol Number: RG_11-187 Start Date*: 2012-06-08
    Sponsor Name:The University of Birmingham
    Full Title: Phase II Randomised Trial of 5-Azacitidine versus 5-Azacitidine in combination with Vorinostat in patients with Relapsed Acute Myeloid Leukaemia ineligible for Intensive Chemotherapy
    Medical condition: Haematological Malignancy - Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-003624-37 Sponsor Protocol Number: CA180-188 Start Date*: 2007-11-16
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START or CA180039 Protocols: Lon...
    Medical condition: Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009012 Chronic myelogenous leukemia LLT
    9.1 10034877 Philadelphia chromosome positive LLT
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) GB (Completed) IT (Completed) FI (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-003617-27 Sponsor Protocol Number: 1230.4 Start Date*: 2008-11-07
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in...
    Medical condition: patients with acute myeloid leukaemia (AML) that are not eligible for intensive treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004761-17 Sponsor Protocol Number: SG033-0003 Start Date*: 2008-05-14
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older with Previo...
    Medical condition: acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) HU (Prematurely Ended) AT (Completed) PL (Prematurely Ended) BG (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-001076-38 Sponsor Protocol Number: GMI-1271-301 Start Date*: 2018-12-21
    Sponsor Name:GlycoMimetics, Inc.
    Full Title: A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) NL (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 23:05:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA